GlassScriptPhysician profile
Sharif I Murphy
NPI 1588096556
$1,634.37
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2021: $92.76 · 2022: $573 · 2023: $477 · 2024: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735 · Education: $59.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.83 |
| Education | $59.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.90 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.81 | 2022-2023 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $88.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.20 | 2021-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $65.97 | 2022-2023 | Dupixent |
| Janssen Biotech, INC. | $58.49 | 2022-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $57.83 | 2022 | |
| Pfizer INC. | $57.32 | 2021-2023 | |
| Boston Scientific Corporation | $52.67 | 2023-2024 | Compliance Endokit, Interject |
| Celgene Corporation | $46.53 | 2022-2023 | |
| Celltrion USA INC. | $37.04 | 2024 | Zymfentra |
| Redhill Biopharma INC. | $28.60 | 2022 | |
| Intercept Pharmaceuticals, INC. | $23.97 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $22.80 | 2022 | |
| Ambu INC. | $19.49 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $17.54 | 2023 | Endoclot Sis, Endoclot Phs |
| Lilly USA, LLC | $17.53 | 2024 | |
| Endogastric Solutions, INC | $17.48 | 2022-2023 | Esophyx |
| Evoke Pharma, INC. | $16.31 | 2024 | |
| Genzyme Corporation | $13.94 | 2024 | |
| Amgen INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharif Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.